Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Calls for Greater Compliance With FAR Reporting Requirements

This article was originally published in The Gold Sheet

Executive Summary

FDA examines field alert report data for early warnings of emerging quality issues, but finds only questions as many companies submit few if any FARs to the agency. Meanwhile, some manufacturers are finding benefits from reporting and dealing with drug defects and errors, improving corporate culture and in one case saving nearly $1 billion.

You may also be interested in...

Pfizer Suffered 'Significant Loss Of Control' At McPherson Plant, US FDA Warning Letter Says

Infractions that have delayed Copaxone generic in plant Pfizer acquired when it bought Hospira suggest that pattern of quality issues may be continuing. Warning letter assigns eight tasks related to particulate contamination.

For Generics and Brand Firms, Complaints Drove Recalls in 2015

Customer complaints and internal quality systems activities drove brand/generic recalls last year while FDA was away inspecting compounding pharmacies.

Hospira Halts Shipment Of Two Drugs After FDA Warning Letter

Voluntary hold on Propofol, Liposyn will negatively impact 2010 sales, though acquisition of Orchid will help make up the difference.

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts